Physician profile
Hernando Moreno
NPI 1396950994
$3,785.22
in general payments reported to CMS, 2019-2025
30 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $370 · 2021: $788 · 2022: $346 · 2023: $556 · 2024: $233 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $632.74 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $527.34 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $427.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $379.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $246.57 | 2019-2021 | |
| Lilly USA, LLC | $168.97 | 2020-2025 | Amyvid, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $167.70 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $127.20 | 2019 | |
| Dexcom, INC. | $121.00 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $112.69 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $109.39 | 2022-2024 | |
| Axsome Therapeutics, INC. | $75.64 | 2024-2025 | Auvelity |
| Nestle Healthcare Nutrition INC. | $69.92 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $69.12 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.81 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.06 | 2021-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $55.92 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $45.00 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $42.09 | 2023 | Gemtesa |
| Eisai INC. | $41.81 | 2021-2025 | |
| Abbvie INC. | $33.68 | 2021-2023 | |
| Amgen INC. | $29.42 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.40 | 2019-2022 | |
| Boston Scientific Corporation | $27.98 | 2025 | Watchman Access System |
| Daiichi Sankyo INC. | $22.95 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.60 | 2021 | |
| Seqirus USA INC | $18.84 | 2025 | Fluad, Flucelvax |
| Allergan, INC. | $18.07 | 2020 | |
| Paratek Pharmaceuticals, INC. | $16.20 | 2025 | Nuzyra |
| Ibsa Pharma INC. | $13.55 | 2025 | Tirosint, Flector, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernando Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.